SCHEMBL166734

SCHEMBL166734

CCOC(=O)c1nc(Cl)nc(N)c1[N+](=O)[O-]

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.41
CYP1A2 P05177 1/20 0.41
NPC1 O15118 3/20 0.41
MAPT P10636 7/20 0.41
RECQL P46063 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
PTGS1 P23219 1/20 0.41
PTGS2 P35354 1/20 0.41
KDM4E B2RXH2 2/20 0.38
HTT P42858 2/20 0.38
HPGD P15428 1/20 0.38
LMNA P02545 1/20 0.38
PKM P14618 1/20 0.38
TP53 P04637 1/20 0.36
XBP1 P17861 1/20 0.36
MAPK1 P28482 1/20 0.36
HSD17B10 Q99714 1/20 0.36
TLR9 Q9NR96 1/20 0.36
IGF1R P08069 1/20 0.36
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27631417 0.86 ADORA3 (0.45) ALDH1A1CYP1A2NPC1MAPTRECQL
SCHEMBL58060 0.86 PTGS1 (0.42) ALDH1A1CYP1A2NPC1MAPTRECQL
SCHEMBL7014795 0.85 NPSR1 (0.46) ALDH1A1NPC1MAPTNPSR1KDM4E
SCHEMBL31729190 0.84 PTGS1 (0.39) ALDH1A1NPC1MAPTRECQLNPSR1
SCHEMBL14524709 0.81 PTGS1 (0.39) ALDH1A1NPC1MAPTRECQLNPSR1
SCHEMBL654797 0.77 LMNA (0.44) ALDH1A1NPC1MAPTPTGS1PTGS2
SCHEMBL27631927 0.77 LMNA (0.44) ALDH1A1CYP1A2NPC1MAPTRECQL
Valine SCHEMBL23537554 0.77 PTGS1 (0.35) ALDH1A1CYP1A2NPC1MAPTRECQL
SCHEMBL18913385 0.77 ALDH1A1 (0.45) ALDH1A1CYP1A2NPC1MAPTRECQL
SCHEMBL1397016 0.75 ALDH1A1 (0.44) ALDH1A1CYP1A2NPC1MAPTRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2611802-B1 BICYCLIC AZA-HETEROCYCLES AND THEIR USE BAYER IP GMBH (DE) 2016-02-24 EP disclosed
US-9096592-B2 Bicyclic aza heterocycles, and use thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-08-04 US disclosed
US-20140148433-A1 BICYCLIC AZA HETEROCYCLES, AND USE THEREOF BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-05-29 US disclosed
EP-2611802-A1 BICYCLIC AZA HETEROCYCLES, AND USE THEREOF Bayer Intellectual Property GmbH (DE) 2013-07-10 EP disclosed
WO-2012028647-A1 BICYCLIC AZA HETEROCYCLES, AND USE THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140148433-A1 BICYCLIC AZA HETEROCYCLES, AND USE THEREOF AADAC, PAICS, TPMT ALDH1A1 649/4885CYP1A2 60/4885NPC1 1907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.